By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Positive data presented on Vermillion's OVA1 ovarian cancer test sent the company's stock up almost 27 percent in mid-afternoon trading today.

With less than two hours left to the trading day, Vermillion's shares were trading at $3.10 and went as high as $3.50 earlier in the day. More than 1.1 million shares traded hands, a greater-than-seven-fold increase from the three-month average daily volume of 152,623.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.